Characteristics and outcomes of patients with pediatric‐onset non‐mastocytosis mast cell activation disorders: A CEREMAST study Authors: M. Weiss, J. Rossignol, F. Campeotto, E. Foy, C. Elbany, L. Jaume, L. Geroux, O. Debeaupuis, A. Neuraz, L. Bekel, G. Lezmi, N. Bellon, C. Méni, C. Livideanu, M. Madrange, D. Condé, J. Agopian, C. Michot, F. Villard‐Truc, A. Lachaux, C. Greco, S. Hadj‐Rabia, P. Dubreuil, O. Hermine, C. Bodemer, L. Polivka Published: 2026 ABSTRACT AbstractBackgroundMast cell (MC) activation (MCA) disorders (MCAD) include diseases in which MCs excessively release mediators leading to recurrent manifestations of MCA. MCAD encompasses MCA syndrome (MCAS) which is defined by (i) documented systemic symptoms of MCA, (ii) a 20% increase in serum tryptase level from the individual's baseline plus 2 ng/mL and (iii) a symptom response to MC‐stabilizing drugs. MCAD not fulfilling mastocytosis or all MCAS criteria are referred to as MCAD not otherwise specified (MCAD‐NOS). The aim was to describe the clinical, laboratory characteristics and outcomes of the first pediatric‐onset non‐mastocytosis MCAD cohort.MethodsAll children with the criteria of non‐mastocytosis MCAD managed at the French National Referral Center for MCAD were included. Clinical, laboratory data, and outcomes were recorded.ResultsForty‐four MCAD patients (mean age at onset: 4.3 years) were identified including 36 MCAD‐NOS and 8 idiopathic MCAS. Hereditary‐α‐tryptasemia was identified in 5/33 (15.2%) patients. The spectrum of symptoms concerned most frequently both the skin (100% of children, with urticaria, angioedema, pruritus, and/or flushing) and the gastrointestinal tract (93% patients). We identified two clinical profiles, according to the age at onset. Before 3 years of age, MCAD was associated with persistent gastrointestinal symptoms triggered by various foods (leading to a drastically limited diet), and after 3 years of age with episodic, recurrent, idiopathic, anaphylactic reactions. The administration of H1 and/or H2 antihistamines drugs +/− a leukotriene receptor antagonist resulted in a marked reduction in symptoms.ConclusionThe description of the clinical profiles of pediatric‐onset non‐mastocytosis MCAD may help to avoid diagnostic delay. Abbreviations Centre de Référence Maladies Rares des Mastocytoses (French National Referral Center for Mast Cell Disorders) droplet digital PCR hereditary alpha tryptasemia mast cell mast cell activation mast cell activation syndrome monoclonal mast cell activation syndrome sucrase‐isomaltase deficiency Key messageThe two most important features of MCAD non specified or idiopathic MCAS concern the skin and the gastrointestinal tract. The clinical profile depended on the age at onset: onset before 3 years of age was characterized by chronic, persistent, food‐triggered symptoms in the gastrointestinal tract at least, whereas onset after 3 years of age was characterized by recurrent, episodic, idiopathic, anaphylactic‐like reactions. In both groups, the combination of an antihistamine with a leukotriene receptor antagonist was well tolerated, significantly reduced the patient's symptoms, and increased quality of life. This study will help physicians to better recognize this little‐known entity and may reduce diagnostic delay. The administration of mast‐cell‐stabilizing drugs constitutes a valuable, safe diagnostic test in children with manifestations of mast cell activation. Key message The two most important features of MCAD non specified or idiopathic MCAS concern the skin and the gastrointestinal tract. The clinical profile depended on the age at onset: onset before 3 years of age was characterized by chronic, persistent, food‐triggered symptoms in the gastrointestinal tract at least, whereas onset after 3 years of age was characterized by recurrent, episodic, idiopathic, anaphylactic‐like reactions. In both groups, the combination of an antihistamine with a leukotriene receptor antagonist was well tolerated, significantly reduced the patient's symptoms, and increased quality of life. This study will help physicians to better recognize this little‐known entity and may reduce diagnostic delay. The administration of mast‐cell‐stabilizing drugs constitutes a valuable, safe diagnostic test in children with manifestations of mast cell activation. INTRODUCTION Mast cells (MCs) are tissue‐bound immune cells involved in physiological immune responses but also in the initiation and maintenance of allergic inflammation and other inflammatory conditions. 1 , 2 , 3 , 4 The term “mast cell activation (MCA) disorders” (MCAD) encompasses a group of clinical situations in which MCs inappropriately degranulate and release excessive amounts of chemical mediators. 4 , 5 , 6 , 7 This excessive release causes symptoms mimicking IgE‐mediated allergy and may significantly impair the patient's quality of life. 8 MCAD encompasses MCA syndrome (MCAS) which is defined by the following Vienna consensus criteria 9 , 10 , 11 : (i) documented severe, recurrent, systemic symptoms of MCA involving at least two organ systems—typical MC–triggered manifestations include gastrointestinal symptoms (nausea, abdominal pain, bloating, cramping, and diarrhea), cutaneous signs (urticaria, flushing, pruritus, and angioedema), respiratory symptoms (throat or chest tightness, shortness of breath, and wheezing), and cardiovascular features (hypotension and tachycardia), (ii) a 20% increase in serum tryptase level from the individual's baseline plus 2 ng/mL, within a 2–4 h window after the reaction, 12 and (iii) a symptom response to MC‐stabilizing drugs that either target MC‐derived mediators (e.g., H1 and H2 antihistamines and leukotriene receptor antagonists) and/or suppress MC activation (e.g., cromoglycate, ketotifen, and omalizumab). 5 , 13 , 14 MCAS can be primary, the so‐called monoclonal MCAS (MMAS), in which KIT‐mutated, clonal MCs are detected and an underlying mastocytosis is often found; secondary, where an underlying non‐neoplastic MC disease is detected (usually an IgE‐mediated polysensitization, autoimmune disease, or inflammatory disorder); or idiopathic (i.e., lacking a clear etiology). The latter two are grouped under the term non‐clonal MCAS. Data on the serum tryptase level during an acute episode of MCA are often lacking—except for severe anaphylactic event. Thus, many patients do not fulfill all MCAS criteria, and are referred as “MCA disorder not otherwise specified (MCAD‐NOS)”. 15 Pathophysiological mechanism of MCAD is still unknown. Lyons et al. identified an autosomal dominant genetic trait, hereditary alpha tryptasemia (HαT), related to duplication/amplification of the alpha‐1 allele of TPSAB1, which is associated with increased basal serum tryptase levels (>8 ng/mL). 16 , 17 , 18 While this genetic trait appears to be present in approximately 5%–6% of the general population, 19 it has been significantly more prevalent in patient with mastocytosis, idiopathic anaphylaxis, and grade IV venom anaphylaxis. 20 Furthermore, the association of HαT in patients with MMAS was associated with a more severe phenotype of hymenoptera‐induced anaphylaxis. 18 , 21 , 22 However, the prevalence of HαT and the consequences on the phenotype in non‐clonal MCAD are still unknown. To date, no study has reported a cohort of non‐mastocytosis MCAD in children nor the prevalence of HαT and its impact on the clinical presentation of pediatric MCAD patients. Thus, the objectives of our study on a cohort of patients with pediatric‐onset non‐mastocytosis MCAD were to (i) describe the clinical presentation of this population, (ii) characterize their clinical profiles, (iii) investigate the prevalence of HαT in this specific population, and (iv) assess outcomes. METHODS Study population We performed a retrospective study in the dermatology department at Necker Children's Hospital (Paris, France), which coordinates the pediatric branch of the French National Referral Center for Mast Cell Disorders (Centre de Référence Maladies Rares des Mastocytoses (CEREMAST)). The CEREMAST was established in 2007 and comprises a nationwide network of 20 reference centers in France dedicated to the clinical management of patients with mastocytosis and to advancing research in this field. All children aged from 0 to 15 years old consulting with typical signs of MCA between January 1st, 2017, and July 31st, 2022, were considered for eligibility in the study. Patients were selected from the CEREMAST national cohort involved in pathophysiological studies with information stored in electronic medical records. The study protocol was approved by the local investigational review board (CPPRB Groupe Hospitalier de Paris Necker, Paris, France; reference 03‐01‐05, dated July 7th, 2003, amended in February 2021). Cases of idiopathic MCAS were defined and classified according to the Vienna consensus criteria. 5 , 11 However, in this particular pediatric context, most of the patients did not have a tryptase assay during an episode and were considered as MCAD‐NOS according to Valent et al. Idiopathic anaphylactic reactions were defined as acute, potentially life‐threatening, systemic reactions involving at least two body systems (from among the skin or mucous membranes, respiratory tract, and gastrointestinal tract) for which a triggering factor had not been identified. 23 , 24 Patient selection and data collection The diagnosis of idiopathic MCAS was retained when there were no arguments for primary and secondary MCAS. In order to rule out cutaneous mastocytosis, all patients underwent a rigorous dermatological examination by one of the CEREMAST's dermatologists. All patients were examined by an allergist. When IgE‐mediated allergy was suspected, a careful questioning, skin prick tests and specific IgE assays were performed. The diagnosis of IgE‐mediated allergy was confirmed in case of the presence of an immediate reaction to a specific allergen with positive specific IgE and/or positive skin prick tests. All patients with suspected MCAD without mastocytosis received MC‐stabilizing drugs targeting MC mediator production, secretion or receptor binding. In order to confirm the evolution under treatment, the parents or legal guardian(s) were asked to rate a visual analog scale (VAS) for an improvement in the patient's signs and symptoms after 3 months of treatment. The scale ranged from 0 to 3, with 0 corresponding to no improvement, 1 to a slight improvement, 2 to a moderate improvement, and 3 to a large improvement. All patients with slight to large improvement were considered to have met the third Vienna criteria. Patients who met at least 2 out of the 3 Vienna criteria were included in this descriptive study. The study variables were assessed at disease onset (during a consultation) and during a study visit, at least 3 months after treatment initiation, by the CEREMAST's dermatologists, using an electronic case report form. All patients who had not been reassessed during a study visit were excluded. For all identified patients, the data presented in Table S1 were collected. Screening for KIT mutations For the first 16 enrolled patients, a bone marrow aspirate was collected and tested for KIT mutations (using a highly sensitive technique described previously 25 ) after the patient's parents or legal guardian(s) had given their informed consent. Given the absence of a KIT mutation in these first 16 patients, ethical considerations and the lack of an elevated basal tryptase level prompted us to refrain from performing bone marrow aspiration in the remaining cases as recommended for pediatric patients with mast cell disorders. Screening for hereditary α‐tryptasemia (HαT) HαT screening was performed only when the child was already undergoing a clinically indicated blood draw during the hospital visit; no additional venipuncture was performed solely for this genetic test. Genomic DNA was extracted from peripheral blood using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). TPSAB1 CNV was assessed by droplet digital PCR (ddPCR) with probes targeting specifically α‐ and β‐tryptase sequences as described by Lyons et al. 26 In brief, genomic DNA was quantified with the Nanodrop 2000 instrument (Thermo Fisher Scientific, USA) and adjusted to 20 ng/μL per sample. After DNA digestion with high‐fidelity restriction enzyme BamHI (New England BioLabs, Ipswich, MA), ddPCR reaction mix (Bio‐Rad Laboratories, Munich, Germany) was prepared using published primers and probes for α‐ and β‐tryptase genes and primers and probes for AP3B1 as a reference gene. Droplets were generated with the QX200 AutoDG Droplet Generator, and PCR was performed on T100 Thermal Cycler (Bio‐Rad Laboratories, Munich, Germany). Quantification of the allelic α‐ and β‐tryptase copies was performed on the QX‐200 Droplet Reader and calculated using QuantaSoft Software (Bio‐Rad Laboratories, Munich, Germany) as described. 26 Increased α‐tryptase encoding TPSAB1 copy number consistent with HαT was defined as ≥3 α‐tryptase copies or 2 α‐tryptase copies in the presence of 3 β‐tryptase copies. Statistical analyses Descriptive statistical analyses were performed using the chi‐square test or Fisher's exact test for categorical variables, as appropriate. Continuous variables were compared using the Mann–Whitney U test. Changes in paired binary outcomes before and after treatment were evaluated with McNemar's test. To account for multiple testing, p values were adjusted using the Benjamini–Hochberg procedure to control the false discovery rate (FDR). A two‐sided p value or q value <.05 were considered statistically significant. Statistical analyses were performed in R (version 4.4.1, R Foundation for Statistical Computing, Vienna, Austria). Symptom prevalence in children younger than 3 years and those aged 3 years or older was visualized using a radar chart generated in R (version 4.4.1, packages tidyverse and fmsb). RESULTS Between January 1st, 2017, and July 31st, 2022, a total of 76 patients were referred to the CEREMAST with suspected non‐mastocytosis MCAD. Thirty‐two patients were excluded because of an incorrect diagnosis (n = 7) and/or because they did not come at the study visit (due to loss to follow‐up, refusal to participate or refusal to take the treatment (n = 14)) and/or because they didn't fulfill at least two of the three Vienna criteria, making the diagnosis of MCAD less likely (n = 11). Overall, 44 of the remaining patients had non‐mastocytosis MCAD and so were selected for the study: 8 MCAS (including 6 with anaphylactic episodes) for which the three criteria were fulfilled and 36 MCAD‐NOS (who did not meet the tryptase criterion but met the treatment response criterion) (Figure S1). As required by the inclusion criteria, none of these included patients presented with cutaneous lesions of mastocytosis. The bone marrow aspirate (performed in 16 patients, 36.4%) did not reveal any signs of mastocytosis: atypical MCs, as well as CD2+ and/or CD25+ MCs, were not detected by flow cytometry (FcER1 and CD117). No KIT mutations (in exons 8 to 13 or exon 17) were found in these patients. Characteristics of the study population The main characteristics of the study population (n = 44) are summarized in Table 1. The mean (range) age at onset of symptoms was 4.3 years (0–14), and 13 patients had clinical manifestations of MCA since the first month of life (congenital MCAD, 29.5%). The mean (range) age at diagnosis was 7.3 years. 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 The female to male ratio was 1.3. There was a family history of clinical manifestations of MCA in 11 patients (25%). When considering the medical history of first‐ and second‐degree family members, we noted anaphylactic reactions (including Quincke's edema) for 11 (25%). The distribution of MCA manifestations was as follows: chronic (daily or persistent, e.g., occurring at least twice per week, for example digestive symptoms or chronic rhinitis) in 33 patients (75%), and episodic, recurrent symptoms involving at least two organs, interspersed with symptom‐free periods, in 11 patients (25%). All of these 11 patients presented with episodic recurrent idiopathic anaphylactic reactions. TABLE 1Main characteristics of the study population and the different subgroups, according to the age at onset.CharacteristicTotal = 44 (%)Age at onset <3 years (N = 23)Age at onset > or = 3 years (N = 21) q Value a Sex ratio (female/male)25/19 (1.3)10/13 (0.77)15/6 (2.6).20Age (years) at onset, mean (range)4.3 (0–14)———Age (years) at diagnosis, mean (range)7.3 (1–16)———Congenital MCAS13 (29.5)———Personal historyAtopy b 18 (40.9)9 (39.1)9 (42.9).94CMPA c 3 (10.7)1 (7.1)2 (14.3).79Familial historyClinical manifestations of MCA symptoms11 (25)7 (30.4)4 (19).60Mastocytosis0 (0)0 (0)0 (0)1Urticaria12 (27.3)6 (26.1)6 (28.6).95Inflammatory bowel disease5 (11.4)3 (13)2 (9.5)1Inflammatory rheumatism4 (9.1)1 (4.3)3 (14.3).56Atopy22 (50)12 (53.2)10 (47.6).92Anaphylactic reaction (included Quincke's edema)11 (25)6 (26.1)5 (23.8).95Chronology of symptomsChronic persistent33 (75)22 (95.7)11 (52.4)<.01Episodic recurrent11 (25)1 (4.3)10 (47.6)<.01Cutaneous signsPruritus17 (38.6)8 (34.8)9 (42.9).79Flushing25 (56.8)14 (60.9)11 (52.4).79Urticaria (wheals) d 30 (68.2)15 (65.2)15 (71.4).84Angioedema21 (47.7)8 (34.8)13 (61.9).22Gastrointestinal signsAbdominal pain and cramps38 (86.3)21 (91.3)17 (81).60Diarrhea29 (65.9)23 (100)6 (28.6)<.01Nausea/vomiting18 (40.9)11 (47.8)7 (33.3).56Gastroesophageal reflux11 (25)9 (39.1)2 (9.5).09Reaction to at least one food26 (59.1)20 (87%)6 (28.6)<.01Reactions to >5 foods22 (50)17 (73.9)5 (23.8)<.01ENT signsQuincke's edema8 (18.2)1 (4.3)7 (33.3).08Laryngeal blockage2 (4.5)0 (0)2 (9.5).44Nasal congestion/pruritus23 (52.3)16 (69.6)7 (33.3).08Neuropsychological signsHeadache10 (22.7)3 (13.6)7 (33.3).33Sleep disorders21 (47.7)16 (69.6)5 (23.8).01Agitation9 (20.5)5 (21.7)4 (19)1Anxiety/mood sadness6 (13.6)1 (4.3)5 (23.8).25Cardiorespiratory signsFainting or loss of consciousness17 (38.6)7 (30.4)10 (47.6).46Palpitations7 (15.9)1 (5.3)6 (28.6).15Cough5 (11.4)3 (13)2 (9.5)1Bronchoconstriction9 (20.5)3 (13)6 (28.6).50General symptomsAnaphylactic reactions17 (38.6)3 (13)14 (66.7)<.01Recurrent fever e 11 (25)2 (11.8)9 (39.1).05Drained feeling14 (31.8)5 (21.7)9 (42.9).31Bone and joint pain13 (29.5)6 (26.1)7 (33.3).79Fatigue14 (31.8)5 (21.7)9 (42.9).31Concentration disorders10 (22.7)3 (13)7 (33.3).33School absenteeism f 20 (50)13 (61.9)7 (33.3).31Break in the growth curve g 8 (18.2)5 (21.7)3 (14.3).87Laboratory findingsBasal serum tryptase level (median (range))3.5 (1.2–14.5)4.0 (1.6–13.5)3.3 (1.2–14.5).21 TPSAB1 germline copy number variants gain (n = 33)5 (15.2)2 (10) (n = 20)3 (23) (n = 13).58Treatment receivedH1 antihistamines42 (95.5)———H2 antihistamines32 (72.7)———Leukotriene receptor antagonists29 (65.9)———Combinations of H1 antihistamines and H2 antihistamines32 (72.7)———Combinations of H1 antihistamines, H2 antihistamines, and anti‐leukotrienes26 (59.1)———Abbreviations: CMPA, cow's milk protein allergy; ENT, ear, nose, and throat; MCAS, mast cell activation syndrome. a To account for multiple testing, p values were adjusted using the Benjamini–Hochberg procedure to control the false discovery rate. b None of the 18 patients with a medical history of atopy (either mild atopic dermatitis, intermittent asthma, or mild allergic rhinoconjunctivitis) were receiving systemic treatments for atopy. Flare‐ups of atopy were not obviously linked to flare‐ups of MCA. c For these three patients the MCA symptoms did not improve after the children moved to a dairy‐free diet. None of the other patients displayed allergic manifestations; food‐allergen‐specific IgE assays and skin prick tests to food allergens were negative in all cases (data not shown). d Urticaria (wheals) correspond to recurrent acute urticaria (intermittent, short‐lived flares—wheals—occurring a few times per year). No cases met criteria for chronic urticaria (symptoms on most days for >6 weeks) per current guidelines. e Recurrent fever was reported by patients or families as low‐grade fever episodes (38°C–38.5°C), occurring without signs of infection and frequently associated with other mast cell activation symptoms such as urticaria flares, fatigue, diarrhea, or abdominal pain, often described by families as typical MCAD flares. f School absenteeism was common: 20 of the 40 children of school age (50%) had taken at least 1 day off from school per month as a result of MCA manifestations. Three of these children (15%) missed school once a week, on average, and 9 (45%) missed school several times a week. g Eight patients (18.2%) presented with a break in the growth curve, although the clinical examination and the usual biological exploration were normal in all cases. Main characteristics of the study population and the different subgroups, according to the age at onset. Abbreviations: CMPA, cow's milk protein allergy; ENT, ear, nose, and throat; MCAS, mast cell activation syndrome. To account for multiple testing, p values were adjusted using the Benjamini–Hochberg procedure to control the false discovery rate. None of the 18 patients with a medical history of atopy (either mild atopic dermatitis, intermittent asthma, or mild allergic rhinoconjunctivitis) were receiving systemic treatments for atopy. Flare‐ups of atopy were not obviously linked to flare‐ups of MCA. For these three patients the MCA symptoms did not improve after the children moved to a dairy‐free diet. None of the other patients displayed allergic manifestations; food‐allergen‐specific IgE assays and skin prick tests to food allergens were negative in all cases (data not shown). Urticaria (wheals) correspond to recurrent acute urticaria (intermittent, short‐lived flares—wheals—occurring a few times per year). No cases met criteria for chronic urticaria (symptoms on most days for >6 weeks) per current guidelines. Recurrent fever was reported by patients or families as low‐grade fever episodes (38°C–38.5°C), occurring without signs of infection and frequently associated with other mast cell activation symptoms such as urticaria flares, fatigue, diarrhea, or abdominal pain, often described by families as typical MCAD flares. School absenteeism was common: 20 of the 40 children of school age (50%) had taken at least 1 day off from school per month as a result of MCA manifestations. Three of these children (15%) missed school once a week, on average, and 9 (45%) missed school several times a week. Eight patients (18.2%) presented with a break in the growth curve, although the clinical examination and the usual biological exploration were normal in all cases. In the cohort as a whole, the spectrum of symptoms concerns most frequently the skin (in 100% of patients). Patients presented with recurrent acute urticaria (intermittent, short‐lived flares—wheals—occurring a few times per year) (n = 30, 68.2%), flushing (n = 25, 56.8%), angioedema (n = 21, 47.7%), pruritus (apart from atopy, n = 17, 38.6%), and/or unspecific rashes (n = 3, 6.8%) (Table 1 and Figure 1). Regarding urticaria, symptomatic dermographism was observed in two patients, whereas no cases of cold urticaria or other inducible forms of urticaria were identified. Symptoms associated with the gastrointestinal tract were the second most frequently observed (93%). Patients presented with abdominal pain or cramps (n = 38, 86.3%), chronic diarrhea (n = 29, 65.9%), nausea or vomiting (n = 18, 40.9%), and/or gastroesophageal reflux (n = 11, 25.0%) (Table 1). An endoscopy of the upper gastrointestinal tract was performed in 12 children (27.3%), six presented a secondary (i.e., without germline genetic anomalies) sucrase‐isomaltase deficiency (SID, diagnosed by enzymatic assay) and six did not present any significant anomalies. For the six patients with SID, the gastrointestinal symptoms and skin symptoms were triggered by a broad spectrum of foods (for example histamine‐rich or histamine‐releasing foods) and not just by sucrose and starch (data not shown). The other main symptoms included sleep disorders, defined by more than 3 awakenings/night before 3 years old or 1 after 3 years old (often waking up every 30 min at night for the infants), asthenia, headache, and concentration disorders (Table 1). School absenteeism, defined by at least 1 day off from school per month as a result of MCA manifestations, was common (50%, Table 1). Overall, 17 of 44 patients (38.6%) experienced idiopathic anaphylaxis, and 15 of these patients were treated with epinephrine. Examples of skin manifestations in patients from our pediatric MCAD cohort. (A) Angioedema of the eyelid; (B) Angioedema of the lips; (C, D) Redness and angioedema of the ears; (E) Urticaria; (F) Flush; (G) Angioedema of the right side of the face. The most frequent trigger was food (59.1%) and more than five foods were implicated in 50% of the patients—leading to a drastically limited diet (Table 1). The foods varied widely among patients and did not systematically involve histamine‐rich foods. No immediate systemic reactions were reported after food ingestion. Symptoms appeared from 6 to 48 h after the ingestion of the suspected incriminated food (by parents and doctors). Symptoms improve markedly but do not completely disappear with the exclusion diet. Seventeen patients (38.6%) experienced anaphylactic reactions; in all cases, review of the medical history—non‐immediate onset, absence of a plausible food trigger (no ingestion within the preceding 2 h)—and negative allergy testing (skin prick testing and serum specific IgE) did not support an IgE‐mediated mechanism; these episodes were therefore classified as idiopathic anaphylaxis. After the first consultation at the CEREMAST reference center, the prescribed treatments included second‐generation H1 antihistamines in 95.5% of cases, H2 antihistamines in 72.7%, and leukotriene receptor antagonists in 65.9%. The mean (range) baseline serum tryptase level was 4.4 ng/mL (1.2; 14.5) overall. Data on the serum tryptase level during an acute episode of MCA were available for 8 patients (18.2%), all diagnosed with idiopathic MCAS; the mean (range) value was 21.6 ng/mL (17.9; 25.2), which corresponds to a mean increase of 412%. Genetic analysis TPSAB1 germline copy number variants were assessed in 33 patients for whom DNA samples were available. HαT was identified in 5/33 patients (15.2%). Among the 11 patients not tested, one had a baseline serum tryptase >8 ng/mL, raising suspicion for HαT; the mean (range) baseline tryptase in this untested subgroup was 4.8 ng/mL (1.1–23.8). Among tested patients, the mean (range) baseline serum tryptase level was 9.7 ng/mL (3; 14.5) in patients with HαT and 3.7 ng/mL (1.2; 6.5) in patients without HαT (p < .01). No other significant differences were observed between the two groups, particularly in terms of family history of MCA or other clinical characteristics (data not shown). Patient profiles as a function of age at onset Based on clinical rationale, we prespecified two age‐at‐onset groups (<3 vs. ≥3 years). The cohort split accordingly: 23 patients (52.3%) had onset before age 3, and 21 (47.7%) at age 3 or later (Figure S2). The main differences between the two groups of patients are summarized in Table 1. We found that chronic persistent symptoms were more prevalent in the earlier‐onset group (n = 22/23, 95.7%) than in the later‐onset group (n = 11/21, 52.4%, q < .01). The earlier‐onset group of patients was homogeneous, with a high proportion of individuals with gastrointestinal symptoms such as chronic diarrhea (n = 23, 100% vs. n = 6, 28.6% in the later‐onset group; q < .01) and sleep disorders (n = 16, 69.6% vs. n = 5, 23.8%, q = .01) triggered by foods in 87.0% of cases (vs. 28.6% in the later‐onset group, q < .01), and more than five foods were frequently incriminated (n = 17, 73.9% vs. n = 5, 23.8% in the later‐onset group; q < .01). None of these patients fulfilled the criteria of food protein‐induced enterocolitis syndrome. In the later‐onset group, the symptoms were episodic recurrent in 10 patients (47.6%). The episodic or acute symptoms consisted of abdominal cramps (n = 17, 81%), urticaria (wheals) (n = 15, 71.4%), angioedema (n = 13, 61.9%), Quincke's edema (n = 7, 33.3% in the later‐onset group vs. n = 1, 4.3% in the earlier‐onset group; q = .08) and corresponded to idiopathic anaphylactic reactions in 14 patients (66.7% vs. 3 patients (13.0%) in the earlier‐onset group, q < .01). Six of the eight patients with idiopathic MCAS belonged to the older‐onset group and experienced anaphylactic reactions. No anaphylactic reactions were observed in the two confirmed idiopathic MCAS cases from the early‐onset group. Response to treatment Six of the 44 patients were not included in this analysis because they had recurrent episodes of MCA but were not receiving long‐term treatment. The mean (IQR) improvement in the visual analog scale score (ranging from 0 (no improvement) to 3 (large improvement)) upon treatment was 2.1 (1.4–2.8). The score was 1 for 7 patients (18%), 2 for 20 patients (53%) and 3 for 11 patients (29%). The MCA signs that responded best to treatment were all gastrointestinal signs (Table 2). Night‐time awakenings were dramatically reduced with treatment (100%). The frequency of anaphylactic‐like episodes was also significantly lower after treatment. Table 2 summarized all the symptoms. TABLE 2Clinical symptoms before and after treatment (n = 38 patients b ).Symptom/itemBefore treatment N (%)After treatment N (%) q Value a GeneralPersistent fatigue27 (71.1)17 (44.7)<.01Recurrent fever11 (28.9)2 (5.3).01Drained feeling27 (71.1)19 (50).08CutaneousPruritus26 (68.4)10 (26.3)<.01Flushes31 (81.6)17 (44.7)<.01Urticaria32 (84.2)14 (36.8)<.01Angioedema20 (52.6)5 (13.2)<.01Another unusual rash24 (63.2)9 (23.7)<.01GastrointestinalAbdominal pain33 (86.8)19 (50)<.01Diarrhea31 (81.6)10 (26.3)<.01Nausea and/or vomiting21 (55.3)6 (15.8)<.01Gastroesophageal reflux28 (73.7)11 (28.9)<.01Pollakiuria15 (39.5)5 (13.2)<.01Food avoidance c 30 (78.9)25 (65.8).08ENTQuincke's edema8 (21.1)3 (7.9).14Laryngeal blockage14 (36.8)2 (5.3)<.01Chronic rhinitis/nasal pruritus23 (60.5)6 (15.8)<.01Cardiorespiratory signsPalpitations18 (47.4)7 (18.4)<.01Unexplained cough20 (52.6)7 (18.4)<.01Dyspnea17 (44.7)17 (44.7)1Severe anaphylactic reaction15 (39.5)2 (5.3)<.01Bone and jointsBone, joint, or muscle pain31 (81.6)12 (31.6)<.01Neuropsychological and socialHeadache18 (47.4)8 (21.1)<.01Night‐time awakening31 (81.6)0 (0)<.01Difficulty falling asleep28 (73.7)15 (39.5)<.01Irritability/anxiety/mood disorders33 (86.8)25 (65.8).03Concentration disorders17 (44.7)14 (36.8).71School absenteeism18 (47.4)10 (26.3).01Factors triggering the symptomsFood reaction c 30 (78.9)26 (68.4).14Temperature change26 (68.4)21 (55.3).20Medication20 (52.6)12 (31.6).05Other triggering factors22 (57.9)19 (50).49 a To account for multiple testing, p values were adjusted using the Benjamini–Hochberg procedure to control the false discovery rate. b Six of the 44 patients were not included in this analysis because they had recurrent episodes of MCA but were not receiving long‐term treatment. c Food reactions and food avoidance were slightly less frequent after treatment (mean reductions of 13.3% and 30.3%, respectively) but the manifestations were less severe than before treatment. This was evidenced by the reductions in gastrointestinal signs and symptoms, which were the main food‐induced symptoms. Clinical symptoms before and after treatment (n = 38 patients b ). To account for multiple testing, p values were adjusted using the Benjamini–Hochberg procedure to control the false discovery rate. Six of the 44 patients were not included in this analysis because they had recurrent episodes of MCA but were not receiving long‐term treatment. Food reactions and food avoidance were slightly less frequent after treatment (mean reductions of 13.3% and 30.3%, respectively) but the manifestations were less severe than before treatment. This was evidenced by the reductions in gastrointestinal signs and symptoms, which were the main food‐induced symptoms. DISCUSSION Here, we report the first series describing the clinical and laboratory features of a cohort of children (n = 44) diagnosed with pediatric‐onset non‐mastocytosis MCAD. Our demographic analysis revealed a female predominance (female/male ratio: 1.3), an early disease onset (mean age at onset: 4.3 years), and a relatively high frequency of congenital forms (29.5%). The prevalence of HαT was 15.2% which is significantly higher than in the general population published by Robey et al. (p = .04). 19 Apart from a significant elevation of basal tryptase in the HαT group, the small size of our study did not allow us to identify other significant differences between the two groups. In this context, testing for HαT may be considered in patients with elevated baseline tryptase levels rather than performed systematically in all patients with suspected MCAD. The mean diagnostic delay was 3 years: this is particularly long in a young child and highlights the diagnostic difficulties and lack of awareness of MCAD among physicians. The symptoms associated to skin and gastrointestinal tract were the two most frequently observed in over 90% of patients, which is consistent with the literature data on adult‐onset MCAD. 5 , 27 Figure S3 summarizes the signs and symptoms of pediatric‐onset MCAD. We identified two clinical profiles for pediatric‐onset MCAD, depending on whether the disease had started before or after the age of 3 years (Figure S2). The younger group was homogeneous and was characterized by chronic, persistent symptoms that affected the gastrointestinal tract (diarrhea, gastroesophageal reflux, and abdominal cramps) and were triggered by foods (albeit not through an IgE‐mediated allergic mechanism). More than five foods were involved in 73.9% of cases; this had resulted in a drastically limited diet and a break in the growth curve in 21.7% of the patients. In the older group, the symptoms were episodic and recurrent in almost half the cases, and chronic persistent in 52.4% of the cases. All these episodes corresponded to idiopathic, anaphylactic reactions, including n = 6 patients with a final diagnosis of idiopathic MCAS. Therefore, as in adults, idiopathic MCAS should be considered as a cause of recurrent, idiopathic anaphylaxis. 28 The small number of included patients prevented us from performing cluster analysis. The absence of signs of clonality in the bone marrow aspirates of the first 16 pediatric patients in our cohort led us to discontinue this invasive procedure in children. We acknowledge that KIT clonality in the 28 unassessed patients cannot be entirely excluded; however, the risk–benefit ratio did not justify further invasive testing, and any positive result would have altered classification rather than symptom‐directed management. These findings, together with data from the literature, suggest that isolated clonal bone marrow MCs are likely exceptional in childhood, in contrast to adults. 29 Non‐mastocytosis MCAD may be mistaken for an IgE‐mediated allergy and especially a food allergy. The large number of incriminated foods, the absence of any immediate reactions, and the negative specific IgE assay and skin prick tests make the diagnosis of an IgE‐mediated allergy unlikely. These manifestations constitute a major problem, especially when they occur at the age of food diversification. Treatment with antihistamines and an MC degranulation blocker limited the severity of food reactions and enabled diversification of the concerned children's diets (Table 2). In addition, patient and family education is essential to ensure trigger avoidance, adherence to treatment, and appropriate management of acute reactions, including the use of epinephrine in patients with a history of anaphylaxis. Furthermore, we struggled to obtain data on the serum tryptase level during acute MCA episodes in most of our patients; this was frequently due to practical problems, such as the difficulty of obtaining a blood sample during the children's short episodes of MCA and within the following 1–4 h. Consequently, the Vienna Consensus tryptase criteria were not met in most patients, who were therefore classified as MCAD‐NOS; however, idiopathic MCAS cannot be excluded in some cases, introducing verification bias and diagnostic misclassification. Given that our cohort includes well‐defined phenotypes (e.g., idiopathic MCAS) alongside a less‐defined category (MCAD‐NOS), is retrospective with inherent limitations (including data completeness and selection bias), and that some subgroup analyses were conducted with very small sample sizes, a larger, dedicated prospective study in non‐mastocytosis MCAD phenotypes is warranted to better characterize clinical phenotypes and derive robust biological, molecular, and metabolic biomarkers. These signatures should be trained and analytically validated in the well‐defined groups and then prospectively applied to MCAD‐NOS to test whether they reduce diagnostic uncertainty and enable data‐driven reclassification. Such biomarkers could enable earlier identification (thereby reducing diagnostic delay) and help prevent the overdiagnosis of MCAD. The absence of standardized treatment in children prompted us to suggest a combination of mediator blocking drugs (second‐generation H1 and H2 antihistamines and leukotriene receptor antagonists) modeled on MCAS management in adults. 5 , 13 , 14 The combination of antihistamines and a leukotriene receptor antagonist was effective on MCA symptoms in our population. It is important to note that after an average of 3 years of serial misdiagnosis, this was the first time that our patients had received a treatment that reduced their symptoms and improved their quality of life. One limitation of our study was the wide range of heterogeneous symptoms that are not specific to pediatric‐onset MCAD. Therefore, we have developed algorithms designed to assist clinicians in optimizing the diagnosis and management of pediatric‐onset MCAD, including guidance on the different drugs to use and their dosages (Figures 2 and 3). It is important to always consider a differential diagnosis, namely conditions not involving MCs like endocrine disorders (hypothyroidism, hypoglycemia, etc.), gastrointestinal disorders (chronic inflammatory bowel disease, celiac disease, etc.), and cutaneous disorders (e.g., hereditary or acquired angioedema). Algorithm for the diagnosis of pediatric‐onset MCAD. *Non‐mastocytosis monoclonal MCAS (i.e., patients presenting with a KIT D816V mutation but only two minor systemic mastocytosis criteria) or SM without cutaneous involvement is extremely rare in children, and further details are therefore not provided here. **MCAS criteria: (i) documented systemic symptoms of MCA, (ii) a 20% increase in serum tryptase level from the individual's baseline plus 2 ng/mL and (iii) a symptom response to MC‐stabilizing drugs. ***For these cases, the provisional diagnosis “probable MCAS” may be appropriate. This diagnosis may then change in follow‐up. For example, if a patient with clinical symptoms of MCAS and a diagnostic increase in tryptase did not respond to first‐line therapy such as antihistamines but did respond to second‐line therapy such as an anti‐IgE antibody, the initial diagnosis would be “probable MCAS” and would change to MCAS when a response to second‐line therapy has been documented. DCM, diffuse cutaneous mastocytosis; MC, mast cell; MCA, mast cell activation; MCAD, mast cell activation disorder; MCAD‐NOS, MCA disorder not otherwise specified; MCAS, mast cell activation syndrome; MPCM, maculo‐papular mastocytosis; WHO, World Health Organization. Clinical algorithm for evaluating suspected pediatric‐onset MCAD *If the baseline serum tryptase level is >8 μg/L, a hereditary alpha tryptasemia is highly probable. **In case of multiple medication reactions, treatments should be given as a medical preparation without excipient (or cellulose alone). ***MCAS criteria: (i) documented systemic symptoms of MCA, (ii) a 20% increase in serum tryptase level from the individual's baseline plus 2 ng/mL and (iii) a symptom response to MC‐stabilizing drugs. ENT, ear, nose, and throat; MCA, mast cell activation; MCAD, mast cell activation disorder; MCAS, mast cell activation syndrome. CONCLUSION Pediatric‐onset non‐mastocytosis MCAD has a broad clinical spectrum. The diagnosis is based on the combination of symptoms affecting at least two organs, the symptoms' time scale, duration and/or recurrence, the elimination of differential diagnoses and the often‐dramatic response to antihistamines. Greater awareness of pediatric‐onset MCAD should lead to a reduction in diagnostic wandering and an improvement in the quality of life of these children. FUNDING INFORMATION This research did not receive any specific funding from agencies or organizations in the public, commercial, or not‐for‐profit sectors. L.P. and O.D. were funded by the Bettencourt Schueller Foundation. CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest for this study. Supporting information Figure S1. Figure S2. Figure S3. Table S1.